Arena Pharmaceuticals (NASDAQ:ARNA) Director Harry F. Hixson, Jr. sold 36,900 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $6.31, for a total value of $232,839.00. Following the transaction, the director now directly owns 82,876 shares in the company, valued at approximately $522,948. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares after opening at $6.12 moved to $6.16 on last trade day and at the end of the day closed at $5.96. Company price to sales ratio in past twelve months was calculated as 16.05 and price to cash ratio as 5.89. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a negative weekly performance of -3.56%.
Illumina (NASDAQ:ILMN) SVP Nicholas Naclerio sold 2,000 shares of the company’s stock on the open market in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $133.56, for a total transaction of $267,120.00. Following the completion of the transaction, the senior vice president now directly owns 23,146 shares in the company, valued at approximately $3,091,380. Illumina, Inc. (NASDAQ:ILMN) shares fell -7.89% in last trading session and ended the day on $139.71. ILMN return on equity ratio is recorded as 8.90% and its return on assets is 4.40%. Illumina, Inc. (NASDAQ:ILMN) yearly performance is 123.39%.
Incyte (NASDAQ:INCY) EVP James M. Daly sold 30,555 shares of Incyte stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $47.71, for a total transaction of $1,457,779.05. Incyte Corporation (NASDAQ:INCY) shares moved down -4.00% in last trading session and was closed at $45.41, while trading in range of $45.30 – $47.15. Incyte Corporation (NASDAQ:INCY) year to date (YTD) performance is -10.31%.
XenoPort (NASDAQ:XNPT) Director Paul Berns sold 2,500 shares of XenoPort stock on the open market in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $4.30, for a total value of $10,750.00. Following the transaction, the director now directly owns 2,500 shares in the company, valued at approximately $10,750. XenoPort, Inc. (NASDAQ:XNPT) weekly performance is -1.67%. On last trading day company shares ended up $4.13. XenoPort, Inc. (NASDAQ:XNPT) distance from 50-day simple moving average (SMA50) is -24.42%. Analysts mean target price for the company is $7.80.